IMpower132: Atezolizumab plus platinum‐based chemotherapy vs chemotherapy for advanced NSCLC in Japanese patients

IMpower132 explored the safety and efficacy of atezolizumab plus pemetrexed and platinum‐based chemotherapy as first‐line treatment for advanced non‐small‐cell lung cancer (NSCLC). Key eligibility criteria for the phase 3, open‐label, IMpower132 study included age ≥18 y, histologically or cytologica...

Descripción completa

Detalles Bibliográficos
Autores principales: Nishio, Makoto, Saito, Haruhiro, Goto, Koichi, Watanabe, Satoshi, Sueoka‐Aragane, Naoko, Okuma, Yusuke, Kasahara, Kazuo, Chikamori, Kenichi, Nakagawa, Yuki, Kawakami, Tomohisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
ORIGINAL ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8019191/
https://www.ncbi.nlm.nih.gov/pubmed/33462883
http://dx.doi.org/10.1111/cas.14817

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8019191/
https://www.ncbi.nlm.nih.gov/pubmed/33462883
http://dx.doi.org/10.1111/cas.14817

Ejemplares similares